{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023094","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2026-05-14T20:15:44+00:00","discovered_at":"2026-05-14T20:17:10.145877+00:00","generated_at":"2026-05-14T20:51:11.246622+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track","bullets":["Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.","Cash and restricted cash $6.8M as of Mar 31, 2026; up from $5.8M at Dec 31, 2025.","G&A expenses fell $1.0M to $1.6M; R&D expenses rose to $2.6M from $2.4M.","CLD-401 IND submission expected by end of 2026; AACR data showed T, NK, and γδ T-cell activation.","Entered partnership with TransferAI to use AI platform to streamline CLD-401 IND submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023094","json":"https://secwatch.observer/filing/0001493152-26-023094.json","markdown":"https://secwatch.observer/filing/0001493152-26-023094.md","text":"https://secwatch.observer/filing/0001493152-26-023094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/0001493152-26-023094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:51:11.246622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a66cab79a1f024ba1797b2ea4727640b58ed6e4d","claim":"Calidi Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income net loss attributable to common stockholders of $4.4 million, or $0.43 per share, EPS $0.43 per share.","evidence_excerpt":"The Company reported a net loss attributable to common stockholders of $4.4 million, or $0.43 per share, for the three months ended March 31, 2026, compared to a net loss attributable to common stockholders of $5.0 million, or $2.21 per share, for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/0001493152-26-023094-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"net loss attributable to common stockholders of $4.4 million, or $0.43 per share"},{"label":"EPS","value":"$0.43 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}